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Chronic kidney disease (CKD) is a major health issue for HIV-positive individuals, associat-
ed with increased morbidity and mortality. Development and implementation of a risk score
model for CKD would allow comparison of the risks and benefits of adding potentially neph-
rotoxic antiretrovirals to a treatment regimen and would identify those at greatest risk of
CKD. The aims of this study were to develop a simple, externally validated, and widely appli-
cable long-term risk score model for CKD in HIV-positive individuals that can guide decision
making in clinical practice.
Methods and Findings
A total of 17,954 HIV-positive individuals from the Data Collection on Adverse Events of
Anti-HIV Drugs (D:A:D) study with  3 estimated glomerular filtration rate (eGFR) values
after 1 January 2004 were included. Baseline was defined as the first eGFR > 60 ml/min/
1.73 m2 after 1 January 2004; individuals with exposure to tenofovir, atazanavir, atazana-
vir/ritonavir, lopinavir/ritonavir, other boosted protease inhibitors before baseline were
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Data Availability Statement: Access to the D:A:D
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encourages the submission of concepts for research
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D:A:D Steering Committee using an online research
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Studies/DAD/Submit-research-concept. Once
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feasibility, Statistical power and feasability and
overlap with already approved projects. Uponexcluded. CKD was defined as confirmed (>3 mo apart) eGFR   60 ml/min/1.73 m
2. Pois-
son regression was used to develop a risk score, externally validated on two
independent cohorts.
In the D:A:D study, 641 individuals developed CKD during 103,185 person-years of fol-
low-up (PYFU; incidence 6.2/1,000 PYFU, 95% CI 5.7–6.7; median follow-up 6.1 y, range
0.3–9.1 y). Older age, intravenous drug use, hepatitis C coinfection, lower baseline eGFR,
female gender, lower CD4 count nadir, hypertension, diabetes, and cardiovascular disease
(CVD) predicted CKD. The adjusted incidence rate ratios of these nine categorical variables
were scaled and summed to create the risk score. The median risk score at baseline was
−2 (interquartile range –4 to 2). There was a 1:393 chance of developing CKD in the next
5 y in the low risk group (risk score < 0, 33 events), rising to 1:47 and 1:6 in the medium
(risk score 0–4, 103 events) and high risk groups (risk score   5, 505 events), respectively.
Number needed to harm (NNTH) at 5 y when starting unboosted atazanavir or lopinavir/
ritonavir among those with a low risk score was 1,702 (95% CI 1,166–3,367); NNTH was
202 (95% CI 159–278) and 21 (95% CI 19–23), respectively, for those with a medium and
high risk score. NNTH was 739 (95% CI 506–1462), 88 (95% CI 69–121), and 9 (95% CI
8–10) for those with a low, medium, and high risk score, respectively, starting tenofovir, ata-
zanavir/ritonavir, or another boosted protease inhibitor.
The Royal Free Hospital Clinic Cohort included 2,548 individuals, of whom 94 individuals
developed CKD (3.7%) during 18,376 PYFU (median follow-up 7.4 y, range 0.3–12.7 y). Of
2,013 individuals included from the SMART/ESPRIT control arms, 32 individuals developed
CKD (1.6%) during 8,452 PYFU (median follow-up 4.1 y, range 0.6–8.1 y). External valida-
tion showed that the risk score predicted well in these cohorts. Limitations of this study in-
cluded limited data on race and no information on proteinuria.
Conclusions
Both traditional and HIV-related risk factors were predictive of CKD. These factors were
used to develop a risk score for CKD in HIV infection, externally validated, that has direct
clinical relevance for patients and clinicians to weigh the benefits of certain antiretrovirals
against the risk of CKD and to identify those at greatest risk of CKD.
Introduction
HIV infection has become a chronic, manageable infection with a potential life expectancy ap-
proaching that of individuals without HIV infection [1,2]. Despite vastly improved outcomes
following the introduction of combination antiretroviral therapy (cART) [3], HIV-positive in-
dividuals experience increased morbidity, including chronic kidney disease (CKD) [4,5]. The
prevalence of CKD in HIV infection has been reported to be as high as 33% [6,7], and is higher
in those with both HIV-related risk factors and traditional risk factors, such as diabetes and hy-
pertension [4,8,9]. In addition to immunodeficiency, certain antiretrovirals, including tenofo-
vir, lopinavir/ritonavir, and atazanavir/ritonavir, have also been shown to be associated with
chronic renal impairment [9–12].
Deteriorating renal function and CKD are a major health issue for both HIV-positive and-
negative individuals, associated with both mortality and cardiovascular outcomes [13–15]. As
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5U01AI046362-03], to the Terry Beirn CommunityHIV-positive individuals age, the burden from chronic conditions may increase and identifying
those at greatest risk becomes increasingly important. Risk prediction models, or risk scores,
have been developed for CKD in both HIV-positive and-negative individuals [16–19]. Such
models are not yet widely implemented into routine clinical practice, with concerns about poor
study design and lack of external validation of these scores [20]. Implementation of risk score
models as part of routine care would allow graded consideration of the safest drugs when initi-
ating and switching antiretrovirals, as well as identifying individuals for whom more intensive
renal monitoring may be appropriate.
The aim of this study was to develop a simple, externally validated, and widely applicable
long-term risk score model for CKD in HIV-positive individuals that can guide decision mak-
ing in clinical practice, and to identify those at greatest risk of CKD.
Methods
Ethical and Study Approval
All participating cohorts in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D)
study followed local national guidelines/regulations regarding patient consent and ethical re-
view. Of the countries represented by the participating cohorts, only Switzerland and Australia
required specific ethical approval for the D:A:D study in addition to that required for their na-
tional cohorts (Swiss HIV Cohort Study and Australian HIV Observational Database). France,
Italy, and Belgium did not require specific ethical approval over and above that required for the
individual cohorts (Nice/Aquitaine Cohort, Brussels St. Pierre Cohort, and ICONA Cohort, re-
spectively), and the Netherlands did not require any specific ethical approval since the data
were provided as part of HIV care (ATHENA Cohort). For the EuroSIDA study (which in-
cludes the data from the BASS and Swedish cohorts), each participating site has a contractual
obligation to ensure that data collection and sharing is done in accordance with national legis-
lation; each site principal investigator either maintains appropriate documentation from an
ethical committee (if required by law) or has a documented written statement to say that this is
not required.
Use of data from the Royal Free Hospital Clinic Cohort was approved by the Chairman of
the Ethics Committee. Both the SMART and ESPRIT trials were approved by the institutional
review board at each participating site, and written informed consent was obtained from all
participants. The institutional review board at the University of Minnesota approved the IN-
SIGHT study (0603M83587).
This project and analysis of data was approved by the D:A:D steering committee on 28 No-
vember 2013 and further ratified by the renal working group within D:A:D on 29 April 2014. A
formal project proposal was submitted to the principle investigator of the Royal Free Hospital
Clinic Cohort (M. A. J.) and to the scientific committee of INSIGHT for their approval and re-
lease of data. Approval from the Royal Free Hospital Clinic Cohort was received on 21 May
2014, and from the INSIGHT scientific steering committee on 20 May 2014.
Study Population
The D:A:D study is a prospective cohort collaboration established in 1999 that follows more
than 49,000 HIV-1-positive individuals in Europe, the United States, and Australia; details
have been published previously [21]. Data on routine clinical care, including demographic fac-
tors, antiretroviral therapy (ART), laboratory values, cardiovascular risk factors, and AIDS
events, are collected electronically at enrolment and every 6 mo thereafter. Serum creatinine
measurements have been collected systematically in participating cohorts since January 2004.
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Baseline was defined as the first estimated glomerular filtration rate (eGFR) > 60 ml/min/1.73
m
2 after the later of (1) 1 January 2004 or (2) inclusion into the D:A:D study. eGFR values were
calculated using the Cockcroft-Gault formula [22], standardised for body surface area. Individ-
uals were censored at the earlier of (1) last eGFR or (2) end of clinical follow-up, defined as the
earlier of (1) last visit plus 6 mo or (2) 1 February 2013. Individuals with <3 eGFR measure-
ments (including the baseline eGFR) before the censor date were excluded, as were individuals
with less than 3 mo of follow-up, who could not progress to CKD. CKD was defined as a con-
firmed (>3 mo apart) decrease in eGFR to  60 ml/min/1.73 m
2 [23]. We excluded individuals
with exposure to the potentially nephrotoxic antiretrovirals tenofovir, atazanavir, atazanavir/ri-
tonavir, lopinavir/ritonavir, or other boosted protease inhibitors (any other protease inhibitor
used with ritonavir) before baseline. These antiretrovirals have previously been shown to be re-
lated to renal outcomes [9,24]. Individuals starting the potentially nephrotoxic antiretrovirals
after baseline were included. Individuals with prior exposure to abacavir and indinavir were
not excluded, and the relationship with development of CKD was investigated in models ad-
justing for their use. cART was defined as any regimen containing three or more antiretrovirals
from any class. Hepatitis B, hepatitis C, hypertension, diabetes, and anaemia were defined as in
previous D:A:D analyses (further information available in [11,25]).
Statistical Methods
As CKD can develop over many years and HIV-positive individuals are exposed to antiretrovi-
rals for many years, we aimed to develop a risk score for predicting CKD over the medium
term (5 y). The first stage was to develop a risk score model to identify the non-antiretroviral
factors associated with the development of CKD; the relationship between CKD and the poten-
tially nephrotoxic antiretrovirals was then investigated after adjustment for the demographic
and clinical factors associated with CKD found in stage 1.
In stage 1, Poisson regression was used to determine the risk of CKD using information
known at baseline. This model was developed in individuals who were not previously exposed
to a potentially nephrotoxic antiretroviral, but individuals may have subsequently started one
of these drugs. All potential demographic, HIV-related, and cardiovascular risk factors for
CKD variables were examined univariately, and factors with p < 0.1 were included in a multi-
variate model. All variables not selected for inclusion (p   0.1) were added to the final model
in turn to determine whether their inclusion improved the fit of the model, as evidenced by
p < 0.1 or a lower Akaike information criterion value. Continuous variables were fitted as con-
tinuous linear variables, categorical variables, or continuous non-linear variables with polyno-
mial splines, depending on previously published literature, clinical value, and best
fitting models.
As data on a number of the renal risk factors (smoking status, hypertension, diabetes, and
prior CVD) are not routinely collected worldwide, a short score was derived without these vari-
ables to allow a risk score calculation in those individuals where only basic HIV information is
known. The adjusted incidence rate ratios (aIRRs) from the best fitting model were scaled and
used to determine the components of the risk score. The components were scaled by dividing
all the aIRRs by the smallest and rounding to the nearest whole number. Whole numbers were
used rather than the exact aIRRs to allow the risk score to be easily remembered and calculated.
Quintiles of the derived risk score were used to define five categories of risk; the lowest three
quintiles were combined as the absolute risk in these categories was extremely small, leaving
three risk groups, low (risk score < 0), medium (risk score 0–4), and high (risk score   5). The
Risk-Score for Chronic Kidney Disease in HIV
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eGFR, estimated glomerular filtration rate; IQR,
interquartile range; NNTH, number needed to harm;
PYFU, person-years of follow-up.same categories were used to classify the shortened version of the risk score (short score).
Kaplan-Meier methods were used to determine the probability of CKD at 5 y after baseline.
Derivation of the Best Fitting Model for CKD
Different methods of building the CKD risk score were also investigated to determine whether
similar predictors of CKD were identified. Forward selection, i.e., including the most important
factors first (those with the lowest p-value and/or those with the greatest change in Akaike in-
formation criterion), led to the same model choice, as did backward selection, i.e., fitting all po-
tential explanatory variables and removing them one at a time, depending on their importance.
A priori, specific interactions of clinical relevance (e.g., age and hypertension) were identified
and tested, with appropriate correction for multiple statistical testing. None of the interactions
tested were significant, and therefore the interactions were not included in the CKD risk
score model.
Initiation of Potentially Nephrotoxic Antiretrovirals
Initiation of a potentially nephrotoxic antiretroviral was added as a time-dependant covariate
to the risk score model, including exactly the same patients contributing the same person-years
of follow-up (PYFU), to estimate the possible contribution of potentially nephrotoxic antiretro-
virals to CKD development. All individuals were naïve to these drugs at baseline, but could sub-
sequently start during prospective follow-up. The risk score model from stage 1 was used to
calculate the number needed to harm (NNTH) over 5 y for those at low, medium, and high
risk of CKD. 95% confidence intervals were estimated based on the 95% confidence intervals
from the Kaplan-Meier progression rates.
External Validation of the Risk Score
The risk score was validated using two external cohorts of HIV-positive individuals: the Royal
Free Hospital Clinic Cohort [26] and the control arms (i.e., non-intervention) of the SMART
and ESPRIT trials from the INSIGHT network [27,28]. Inclusion and exclusion criteria were
applied in the same way as for D:A:D study participants; eGFR was calculated using the Chron-
ic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula [29]. Risk score perfor-
mance was evaluated by comparison of the crude incidence rates within risk score strata,
Kaplan-Meier progression rates, and aIRRs associated with a one-point increase in the
risk score.
Calculation of an Individual’s Risk of CKD at t Years
For a given set of characteristics, the probability of progression to CKD in the next t years (e.g.,
5 y) can be calculated using the following formula:
Prob ðsurvival at timetÞ¼1   expð H tÞð 1Þ
where H = exp (β0 + β1X1 + β2X2); X1,X 2, etc., are the covariate values; and β0, β1, β2, etc., are
the parameter estimates from the Poisson regression model.
The population was divided into those at low, moderate, and high risk of CKD for the pur-
pose of explaining the model and to broadly categorise risk of CKD. Individual risk can be cal-
culated as per this formula. The authors will develop an easy-to-use online tool whereby an
individual’s underlying risk of CKD and NNTH depending on types of antiretroviral drugs
used can be estimated by entering the individual’s own characteristics.
Risk-Score for Chronic Kidney Disease in HIV




Of the 49,717 individuals enrolled in the D:A:D study, 36,180 (72.8%) had at least one
eGFR > 60 ml/min/1.73 m
2 after the later of 1 January 2004 or enrolment into the D:A:D
study. Of these 36,180 individuals, 17,954 (49.6%) met entry criteria for and were included in
analyses; 2,645 (7.3%) individuals were excluded because they had <3 eGFR measurements,
308 (0.9%) were excluded because they had no baseline CD4 counts or viral loads, 15,172
(41.9%) were excluded because of prior exposure to potentially nephrotoxic antiretrovirals,
and 101 (0.3%) were excluded because there was <3 mo of follow-up between first eGFR after
baseline and last eGFR. The incidence of CKD in those excluded was 12.7/1,000 PYFU (95% CI
12.0–13.5).
The characteristics of the 17,954 included individuals are shown in Table 1. The median
eGFR at baseline was 104 (interquartile range [IQR] 90–120 ml/min/1.73 m
2); 687 individuals
(3.8%) had an eGFR of >60 to  70 ml/min/1.73 m
2, 3,778 (21.0%) had an eGFR of >70 to
 90 ml/min/1.73 m
2, and 13,489 (75.1%) had an eGFR of >90 ml/min/1.73 m
2. There was a
total of 270,926 eGFR measurements available for analysis, a median of 14 (IQR 9–20) per per-
son, measured a median time of 4 mo (IQR 3–6) apart. During 103,185 PYFU (median follow-
up 6.1 y, range 0.3–9.1 y), 641 developed CKD (3.6%); the incidence of CKD was 6.2/1,000
PYFU (95% CI 5.7–6.7). At 2, 5, and 8 y after baseline, 1.1% (95% CI 0.9%–1.2%), 2.7% (95%
CI 2.4%–2.9%), and 5.3% (95% CI 4.9%–5.8%) were estimated to have developed
CKD, respectively.
Development of the Risk Score and the Short Version Excluding
Cardiovascular Risk Factors
HIV exposure group (intravenous drug user versus all others), gender, hepatitis C coinfection,
age, nadir CD4 count ( 200 cells/mm
3), baseline eGFR, hypertension, diabetes, and prior
CVD at baseline were all significant predictors of CKD and were included in the risk score
model. Both the precise coefficients from the best fitting statistical model and the estimates to
be used in the risk score model are shown in Table 2. Baseline CD4 count, hepatitis B status,
race, smoking status, AIDS ever or in the 12 mo prior to baseline, prior use of other antiretrovi-
rals (including abacavir or indinavir), anaemia, and viral load (as either a continuous or cate-
gorical variable) were not significantly related to CKD after adjustment for the other variables
listed and were excluded from our risk score models.
Also shown in Table 2 is the shortened version of the risk score, which could be used when
cardiovascular risk factors are unavailable. The improvement in event classification by incor-
porating the cardiovascular risk factors in the risk score model was 2.5% (p <0.001). The risk
score model had good discrimination (Harrell’s C-statistic 0.92, 95% CI 0.90–0.93), as did the
short model (Harrell’s C-statistic 0.91, 95% CI 0.90–0.92), although significantly poorer than
the risk score model incorporating cardiovascular risk factors (p < 0.001). The short model
had a significantly higher Akaike information criterion, indicating that the risk score model
provided a better prognostic risk score.
Focusing on the full risk score model, the median risk score at baseline was −2 (IQR −4t o
2). Among those who developed CKD, the median risk score at baseline was 10 (IQR 5–14).
Three risk groups were created, as detailed in the Methods, corresponding to low (risk
Risk-Score for Chronic Kidney Disease in HIV
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All 17,954 100 17,313 96.4 641 3.6
Gender Male 13,130 73.1 12,671 73.2 459 71.6
Female 4,824 26.9 4,642 26.8 182 28.4
Race White 8,361 46.6 8,040 46.4 321 50.1
Black 1,286 7.2 1,264 7.3 22 3.4
Other 356 2.0 348 2.0 8 1.3
Unknown 7,951 44.3 7,661 44.3 290 45.2
HIV exposure Homosexual 8,310 46.3 8,046 46.5 264 41.2
Intravenous drug
user
2,081 11.6 1,995 11.5 86 13.4
Heterosexual 6,578 36.6 6,333 36.6 245 38.2
Other 985 5.5 939 5.4 46 7.2
Hepatitis B Negative 11,070 61.7 10,699 61.7 371 57.9
Positive 1,633 9.1 1,574 9.1 59 9.2
Unknown 5,251 29.2 5,046 29.2 211 32.9
Hepatitis C Negative 11,386 63.4 10,995 63.4 391 61.0
Positive 2,262 12.6 2,173 12.6 89 13.9
Unknown 4,306 24.0 4,145 24.0 161 25.1
Antiretroviral use Naïve 9,325 51.9 9,126 52.7 199 31.0
ART 512 2.9 488 2.8 24 3.7
cART 8,117 45.2 7,699 44.5 418 65.2
Smoking status Current 7,439 41.4 7,219 41.7 220 34.3
Previous 3,111 17.3 2,956 17.1 155 24.2
Never 5,019 28.0 4,812 27.8 207 32.3
Unknown 2,385 13.3 2,326 13.4 59 9.2
Hypertension 1,448 8.1 1,328 7.7 120 18.7
CVD 295 1.6 251 1.5 44 6.9
AIDS 2,628 14.6 2,469 14.3 159 24.8
Recent AIDS (in last 12 mo) 610 23.2 586 23.7 24 15.1
Diabetes 562 3.1 494 2.9 68 10.6
Anaemia
1 3,019 22.3 2,852 21.8 167 33.3
Viral load < 400 7,913 44.1 7,515 43.4 398 62.1
Age (years) 40 34–47 40 33–46 56 47–64
CD4 count (cells/mm
3) 460 320–643 460 320–644 440 300–615
Nadir CD4 count (cells/mm
3) 290 169–434 292 170–438 202 93–337
Date of baseline eGFR
2 (month/
year)
6/05 5/04–1/07 6/05 5/04–2/07 1/05 5/04–1/06
Baseline eGFR
2 (ml/min/1.73 m
2) 104 90–120 105 91–121 73 65–84
1Baseline haemoglobin known for 13,568 (75.6%) overall: 13,067 (75.5%) among those who did not develop CKD, and 501 (78.2%) among those who
developed CKD.
2First eGFR > 60 ml/min/1.73 m
2 after later of 1 January 2004 or enrolment into the D:A:D study.
doi:10.1371/journal.pmed.1001809.t001
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score   5, 505 events [78.8%]). There was a clear increase in incidence of CKD moving from
the low to high risk score group (Table 3), and these rates and proportions reflect the underly-
ing risks of CKD in individuals not exposed to potentially nephrotoxic antiretrovirals; there
was a 0.18% probability of developing CKD over the next 5 y in the low risk group (95% CI
0.09%–0.26%), increasing to 1.50% (95% CI 1.09%–1.91%) and 14.68% (95% CI 13.24%–
16.12%) in the medium and high risk groups, respectively. Finally, there was a 1:393 chance of
developing CKD in the next 5 y in the low risk group, rising to 1:47 and 1:6 in the medium and
high risk groups, respectively.
Table 2. Models for risk score for CKD: full risk score and short risk score.
Characteristic Subcategory Full Risk Score Model Example of Calculation for
Full Risk Score Model













1 −6.2406 0 −6.2059





0.6556 2 0.6481 2
Hepatitis C
coinfection
Negative 0 X 0 0
Positive 0.3395 1 0.3288 1
Age (years)  35 0 0
>35 to  50 1.0813 4 X 4 1.1114 4
>50 to  60 2.0276 7 2.1166 7




>60 to  70 1.6475 6 X 6 1.6254 6
>70 to  90 0 0
>90 −1.6365 −6 −1.6242 −6
Gender Male 0 0




 200 0 0
>200 −0.2848 −1X −1 −0.2931 −1
Hypertension
2 No 0 X 0
Yes 0.2386 1
Prior CVD




Yes 0.5764 2 X 2
Individuals with unknown values for hepatitis, hypertension, prior CVD, and diabetes were included in the “no” category for those factors after comparing
the coefﬁcients from the multivariate model. Models excluding those with unknown data showed similar factors associated with CKD, and a similar relative
contribution from each of the factors considered.
1For use if the exact risk is to be calculated.
2See [11] for further information.
doi:10.1371/journal.pmed.1001809.t002
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There were 55,010 eGFR measurements included from the Royal Free Hospital Clinic Cohort
from 2,548 individuals; 94 individuals developed CKD (3.7%) during 18,376.0 PYFU (inci-
dence 5.1/1,000 PYFU; 95% CI 4.1–6.1; median follow-up 7.4 y, range 0.3–12.7 y). Characteris-
tics are shown in S1 Table. Information on diabetes, CVD, and hypertension was not routinely
recorded in this cohort, and hence the short risk score was validated, as summarised in Table 3.
There were 11,088 eGFR measurements included from the SMART/ESPRIT trials from
2,013 individuals; 1,036 (51.5%) were from ESPRIT. In total, 32 individuals developed CKD
(1.6%) during 8,451.7 PYFU (incidence 4.1/1,000 PYFU, 95% CI 2.2–5.9; median follow-up 4.1
y, range 0.6–8.1 y). Cohort characteristics are shown in S1 Table. Information on diabetes, hy-
pertension, and prior CVD was available within the SMART/ESPRIT cohorts, and hence the
full risk score was validated (Table 3).
Although the number of events was considerably smaller in the validation cohorts than in
the derivation cohort, resulting in comparatively wide 95% confidence intervals, the incidence
rates were similar and increased across the low, medium, and high risk score groups (Table 3).
Incidence rates across derivation and validation cohorts were similar, and the aIRR associated
with a one-point increase in the score was virtually identical in all cohorts, using the full risk
score or the short version. Kaplan-Meier progression in those with low, medium, and high risk
scores was also very similar in both of the validation cohorts and the D:A:D derivation cohort
(Fig. 1; Table 3). The short risk score showed good discrimination in the Royal Free Hospital
Clinic Cohort (Harrell’s C-statistic 0.86, 95% CI 0.78–0.90), as did the full risk score in the
SMART/ESPRIT cohort (Harrell’s C-statistic 0.87, 95% CI 0.80–0.94).








Validation Royal Free Hospital
Clinic Cohort (Short Risk Score)
N 17,954 17,954 2,013 2,548
Developed CKD, N (percent) 641 (3.6) 641 (3.6) 32 (1.6) 94 (3.7)
Incidence of CKD/1,000 PYFU (95% CI) 6.2 (5.7–6.7) 6.2 (5.7–6.7) 3.8 (2.5–5.1) 5.1 (4.1–6.1)
Risk score model
Baseline score, median (IQR) −2( −4t o2 ) −2( −4t o2 ) −2( −3t o1 ) −2( −5t o0 )
Baseline score for those who developed CKD,
median (IQR)
10 (5–14) 10 (5–13) 9 (0–12) 5 (1–9)
Events by score group: low/medium/high 33/103/505 37/112/492 6/7/19 18/21/55
Incidence of CKD/1,000 PYFU (95% CI)
Low (risk score < 0) 0.51 (0.34–0.69) 0.56 (0.38–0.75) 1.07 (0.39–2.32) 1.32 (0.78–2.08)
Medium (risk score 0–4) 4.27 (3.45–5.10) 4.67 (3.80–5.53) 3.40 (1.35–6.92) 6.55 (3.75–9.35)
High (risk score   5) 34.75 (31.72–37.78) 36.05 (32.86–39.23) 25.90 (15.60–40.50) 36.33 (26.73–45.93)
Incidence rate ratio (95% CI)
Low (risk score < 0) 0.12 (0.081–0.18) 0.12 (0.08–0.18) 0.32 (0.11–0.94) 0.20 (0.11–0.38)
Medium (risk score 0–4 ) 1111
High (risk score   5) 8.13 (6.58–10.05) 7.73 (6.29–9.49) 7.71 (3.24–18.35) 5.55 (3.36–9.18)
Kaplan-Meier percent progressed at 5 y (95%
CI)
Low (risk score < 0) 0.18 (0.09–0.26) 0.19 (0.10–0.27) 0.38 (0.10–0.81) 0.35 (0.04–0.66)
Medium (risk score 0–4) 1.50 (1.09–1.91) 1.62 (1.19–2.05) 1.64 (0.15–3.13) 1.71 (0.34–3.08)
High (risk score   5) 14.68 (13.24–16.12) 15.33 (13.82–16.84) 11.30 (5.62–16.98) 15.00 (9.90–20.10)
aIRR (95% CI) per unit increase in score 1.32 (1.30–1.34) 1.33 (1.31–1.34) 1.30 (1.23–1.37) 1.29 (1.25–1.33)
doi:10.1371/journal.pmed.1001809.t003
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Harm
Table 4 shows the initiation of antiretrovirals after baseline. For example, 11,153 individuals
started tenofovir during prospective follow-up (62.1%), and 9,854 had started the drug by 5 y
after baseline, corresponding to 61.2% (95% CI 60.4%–62.0%) starting tenofovir by 5 y using
Kaplan-Meier estimation. Initiation of a potentially nephrotoxic antiretroviral was added to
the risk score model as a time-dependant covariate to estimate contribution of potentially
Fig 1. Kaplan Meier progression to chronic kidney disease with low, medium, and high risk scores.
(A) D:A:D study: derivation cohort. (B) Royal Free Hospital Clinic Cohort: validation cohort. (C) SMART/
ESPRIT control arms: validation cohort.
doi:10.1371/journal.pmed.1001809.g001
Risk-Score for Chronic Kidney Disease in HIV
PLOS Medicine | DOI:10.1371/journal.pmed.1001809 March 31, 2015 10 / 31nephrotoxic antivirals to the risk of CKD and to calculate the NNTH for those at low, medium,
and high risk of CKD. Individuals starting tenofovir, atazanavir/ritonavir, or any other boosted
protease inhibitor (excluding lopinavir/ritonavir) had an increased risk of CKD equivalent to a
two-point increase in the risk score, or a 74% increased incidence of CKD (aIRR 1.74, 95% CI
1.69–1.78) compared to individuals not starting these drugs but with otherwise similar risk fac-
tors for CKD. Those starting atazanavir or lopinavir/ritonavir had an increased risk of CKD
equivalent to a one-point increase in the risk score, or a 32% increased incidence of CKD
(aIRR 1.32, 95% CI 1.30–1.34) compared to those not starting these drugs but with otherwise
similar risk factors for CKD.
NNTH values are summarised in Fig. 2. The NNTH is the average number of individuals
who could be treated with one of the potentially nephrotoxic antiretrovirals for one extra per-
son to develop CKD compared to if the same individuals had not received this treatment.
There is a clear decrease in NNTH moving from low to high risk score group for CKD, suggest-
ing much greater potential harm with these potentially nephrotoxic antiretrovirals in individu-
als at high risk of CKD compared to those at low risk. For example, starting or adding
tenofovir, atazanavir/ritonavir, or another boosted protease inhibitor (excluding lopinavir/rito-
navir) gave a NNTH of 739 over 5 y in those at low risk of CKD. Thus, on average, treating 739
individuals (95% CI 506–1,462) with tenofovir in the low risk group would yield one extra case
of CKD relative to if the same 739 individuals were not treated with this drug. Starting or add-
ing unboosted atazanavir or lopinavir/ritonavir in the low risk group gave a NNTH of 1,702
over 5 y (95% CI 1,166–3,367). In the medium risk group (risk score 0–4), the NNTH was 88
(95% CI 69–121) for tenofovir, atazanavir/ritonavir, or another boosted protease inhibitor (ex-
cluding lopinavir/ritonavir) and 202 (95% CI 159–278) for unboosted atazanavir or lopinavir/
ritonavir, over 5 y. These NNTH values decreased markedly in the high risk group (risk
score   5), to 9 (95% CI 8–10) and 21 (95% CI 19–23), respectively, over 5 y.
The NNTH is for addition of each potentially nephrotoxic antiretroviral as a single drug; in
practice they are commonly combined. For example, a person starting tenofovir with lopina-
vir/ritonavir would have a 2.29-fold increased incidence of CKD (1.74—fold increase from
tenofovir and 1.32-fold increase from lopinavir/ritonavir), equivalent to a three-point increase
Table 4. Use of potentially nephrotoxic antiretrovirals during follow-up in among 17,954 individuals in the D:A:D study.
Outcome Tenofovir Atazanavir Atazanavir/r Lopinavir/r Other PI/r Any of These
Started ARV, N (percent)
After baseline 11,153 (62.1) 1,078 (6.0) 3,441 (19.2) 3,240 (18.1) 440 (2.5) 12,641 (70.4)
By 1 y 3,668 (20.4) 316 (1.8) 992 (5.5) 898 (5.0) 96 (0.5) 4,448 (24.8)
By 2 y 5,655 (31.5) 497 (2.8) 1,628 (9.1) 1,445 (8.0) 183 (1.0) 6,988 (38.9)
By 5 y 9,854 (54.9) 799 (4.5) 2,744 (15.3) 2,515 (14.0) 317 (1.8) 11,474 (63.9)
Developed CKD and started ARV after
baseline, N (percent)
366 (57.1) 46 (7.2) 162 (25.3) 128 (20.0) 16 (2.5) 434 (67.7)
Kaplan-Meier percentage started ARV,
percent (95% CI)
At 1 y 19.3 (18.7–19.9) 0.8 (0.7–1.0) 5.0 (4.7–5.3) 7.6 (7.2–8.0) 0.7 (0.6–0.8) 24.9 (24.2–25.5)
At 2 y 32.3 (31.6–33.0) 1.8 (1.6–2.0) 9.4 (9.0–9.8) 11.4 (10.9–11.8) 1.3 (1.1–1.4) 39.8 (39.1–40.6)
At 5 y 61.2 (60.4–62.0) 5.2 (4.8–5.5) 18.7 (18.1–19.3) 18.7 (18.1–19.3) 2.5 (2.3–2.8) 70.6 (69.8–71.3)
All individuals were naïve to these antiretrovirals at baseline.
/r, ritonavir boosted; ARV, antiretroviral; PI, protease inhibitor.
doi:10.1371/journal.pmed.1001809.t004
Risk-Score for Chronic Kidney Disease in HIV
PLOS Medicine | DOI:10.1371/journal.pmed.1001809 March 31, 2015 11 / 31in the risk score. This equates to a NNTH of 436 (95% CI 298–861) for those at low risk, 52
(95% CI 41–71) for those at medium risk, and 5 (95% CI 5–7) for those at high risk.
Calculation of an Individual Risk Score
Using Table 3, a person who is female (+1), who does not use intravenous drugs (+0), without
hepatitis coinfection (+0), aged 38 y (+4), who has an eGFR of 68 ml/min/1.73 m
2 (+6), with a
nadir CD4 count of 250 cells/mm
3 (−1), without hypertension (+0) or prior CVD (+0), but
with diabetes (+2) would have a risk score of 12, placing her in the high risk category. On aver-
age, 14.68% (95% CI 13.24%–16.12%) of individuals in this study with a high risk of CKD pro-
gressed to CKD by 5 y after baseline.
Fig 2. Number needed to harm among those at low (risk score < 0), medium (risk score 0–4), or high
risk (risk score   5) of CKD. ATV, atazanavir; ATV/r, atazanavir/ritonavir; BPI, other ritonavir-boosted
protease inhibitor (excluding lopinavir/ritonavir and atazanavir/ritonavir); LPV/r, lopinavir/ritonavir;
TDF, tenofovir.
doi:10.1371/journal.pmed.1001809.g002
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characteristics can be used to calculate the exact probability of the risk of CKD at 5 y and esti-
mate how that risk changes if one of the potentially nephrotoxic antiretrovirals is started. Thus
a person who is female (+0.3982), who does not use intravenous drugs (+0), without hepatitis
coinfection (+0), aged 38 y (+1.0813), who has an eGFR of 68 ml/min/1.73 m
2 (+1.6475), with
a nadir CD4 count of 250 cells/mm
3 (−0.2848), without hypertension (+0) or prior CVD (+0),
but with diabetes (+0.5764) would have an exact risk score of 3.4186, added to the constant
(representing the intercept of the model) of −6.2406, giving a total score (H)o f−2.822, corre-
sponding to a 25.7% risk of developing CKD in 5 y; adding tenofovir would increase that risk
to 44.7% (i.e., a 74% increase in risk of CKD in those starting tenofovir); adding tenofovir and
lopinavir/ritonavir would increase the risk to 58.9% (i.e., a 123% increase in risk). In contrast, a
person who is male (+0), who does not use intravenous drugs (+0), without hepatitis coinfec-
tion (+0), aged 28 y (+0), who has an eGFR of 80 ml/min/1.73 m
2 (+0), with a nadir CD4
count of 250 cells/mm
3 (−0.2848), without hypertension (+0), prior CVD (+0), or diabetes
(+0) would have an exact risk score of −0.2848, added to the constant (representing the inter-
cept) of −6.2406, giving a total score (H)o f−6.5254, corresponding to a 0.7% risk of developing
CKD within the next 5 y, increasing to 1.2% if tenofovir is included as part of his antiretroviral
regimen, and to 1.6% if he starts tenofovir and lopinavir/ritonavir.
Discussion
We developed a simple, clinically useful risk score for predicting CKD at 5 y in individuals
with HIV, and validated the score in two clinically diverse populations with different frequen-
cies of eGFR monitoring. We have calculated the NNTH over 5 y when starting tenofovir or
other potentially nephrotoxic antiretrovirals in individuals with high, medium, or low underly-
ing risk of CKD. The development of a publicly available online tool estimating an individual’s
5-y risk of CKD with or without the addition of potentially nephrotoxic antiretrovirals enables
clinicians and HIV-positive individuals to make an informed decision about acceptable risk for
an individual’s care, relative to the benefits of any given treatment regimen, and to identify
those at greatest risk of CKD.
Previous research from the D:A:D study showed similar risk factors for end-stage renal dis-
ease/advanced CKD, and showed that those on tenofovir had lower rates of this more advanced
end point [30]. The most likely reason for this finding was that tenofovir, especially, was dis-
continued as eGFR declined, likely leaving a highly selected group of individuals at low risk of
end-stage renal disease taking the drug. The previous study differs from that presented here in
two important ways: by considering a less advanced deterioration in kidney function than
CKD, and by considering the medium- to long-term risk of CKD to develop a risk score. Age,
HIV exposure route, hepatitis C coinfection, gender, nadir CD4 count, hypertension, CVD,
and diabetes, have all been previously shown to be associated with CKD [4,19,31], so their in-
clusion in our score was expected. The factors included in our risk score model, and the num-
ber of points these factors contributed to the risk score, highlight the need for patient
monitoring, screening, and chronic disease prevention to minimise the risks of developing dia-
betes, hypertension, or CVD, as well as the risk of becoming hepatitis C virus coinfected.
The risk score model presented here establishes the demographic, traditional, and HIV-as-
sociated risk factors for CKD in those naïve to potentially nephrotoxic antiretrovirals. The anti-
retrovirals included in the model were chosen a priori based on previous research and include
those suggested to have a potentially nephrotoxic effect [9,24]; we did not consider other anti-
retrovirals as they have not been shown to be associated with CKD. The potentially nephrotox-
ic antiretrovirals were then added as time-updated variables to estimate the increased risk of
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tors for CKD. In addition, we developed a short version of the risk score excluding cardiovascu-
lar information—not always routinely available in HIV cohorts—which showed good
agreement with the full risk score and also good agreement with external validation. The short
version of the risk score could be widely used to assess renal risk in developing countries. The
DART trial reported 5% of individuals with HIV developing CKD at 4 y, higher than the 2.7%
overall found in the D:A:D study, and concluded that first-line ART, including tenofovir, could
be used without renal monitoring [32]. The risk score developed here found that the risk of
CKD was very low for the majority of HIV-positive individuals, and hence the NNTH from
adding potentially nephrotoxic antiretrovirals was high, confirming the results from the DART
trial, which primarily included individuals at low risk of CKD, and suggesting that such antire-
trovirals can be started with minimal additional risk of CKD, subject to appropriate monitor-
ing. In the high risk group (risk score   5), the NNTH was much lower, and routine renal
monitoring in such patients, or the use of an alternative non-nephrotoxic antiretroviral if avail-
able, seems warranted in such high risk populations.
We validated both the full risk score and the short version, excluding important cardiovas-
cular risk factors, on quite diverse populations. The Royal Free Hospital Clinic Cohort is a clin-
ic-based cohort with a lower proportion of older individuals or intravenous drug users, while
individuals from the randomised SMART/ESPRIT trials were from many centres worldwide
[27,28]. As stated, we cannot adjust fully for race in the D:A:D study, and so we used the Cock-
croft-Gault formula for estimating eGFR [22], adjusted for body surface area. Research from
EuroSIDA has shown that eGFRs derived from the Cockcroft-Gault and CKD-EPI formulae
predict CKD equally well in European patients [33]. The CKD-EPI formula was used in the
validation cohorts to demonstrate that the risk score had good discrimination and was not sen-
sitive to the choice of formula for calculating eGFR. Despite differences between the validation
cohorts and the derivation cohort in frequency of and method for calculation of eGFR, there
was remarkable agreement between the different studies in the increased incidence of CKD as-
sociated with a unit increase in the risk score and in the incidence rates of CKD within each
risk score group, and excellent discrimination between those developing and not developing
CKD.
There are several limitations to this study; we excluded over half of the D:A:D study popula-
tion in order to determine risk factors for CKD in individuals naïve to potentially nephrotoxic
antiretrovirals and to determine the subsequent medium-term increased risk of CKD when in-
dividuals at high, medium, or low risk of CKD start such drugs. Limitations on data collection
meant we were not able to fully adjust for race, and further validation in this subgroup should
be considered. Unmeasured confounding can never be excluded in observational studies. Our
model considered only antiretrovirals previously suggested to have a nephrotoxic effect (teno-
fovir, atazanavir/ritonavir, and boosted protease inhibitors excluding lopinavir/ritonavir), and
we cannot exclude the possibility that other antiretrovirals not included in these analyses may
also increase the risk of CKD. Routine screening for proteinuria in HIV-positive individuals,
which is associated with CKD in HIV infection, has only recently been implemented, and pro-
teinuria screening data are not yet available in the D:A:D study and could not be included in
our risk score model. We encourage other cohorts with available data to determine whether in-
cluding such information improves the predictive ability of the D:A:D risk score, as well as to
further develop the risk score to incorporate other prognostic information for CKD. A recently
derived risk score for CKD in HIV-positive men, including proteinuria, suggested that similar
clinical and laboratory markers were associated with CKD. Importantly, this study considered
the impact of only tenofovir [19] and not other potentially nephrotoxic antiretrovirals, and was
not externally validated
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ly calculable, and implementable measure of future risk of CKD in HIV-positive individuals
that facilitates an individualised approach to management by allowing calculation of the risk of
CKD for a given set of characteristics, and then investigation of how that risk changes if poten-
tially nephrotoxic antiretrovirals are added to the treatment regimen. The tool is available at
http://hivpv.org/Home/Tools/ChronicKidneyDiseaseTool.aspx. The 2013 revised WHO guide-
lines recommend targeted creatinine testing for HIV-positive individuals taking tenofovir and
for those with hypertension [34]. CKD is a multifactorial process, and resources might be better
utilised by more frequent or targeted testing in those with a high risk score, which incorporates
many different risk factors. The NNTH shows that adding potentially nephrotoxic antiretrovi-
rals to the treatment regimen for patients at low underlying risk of CKD should not cause
undue concern and that the benefits likely outweigh the risks. Conversely, the use of such anti-
retrovirals in individuals with a high underlying risk of CKD needs careful discussion and close
monitoring. Risks and benefits, both renal and for other comorbidities, and already acquired
HIV drug resistance clearly need to be carefully assessed when choice of antiretroviral drugs
and intensity of monitoring is decided on in this group of individuals. The shorter version of
the risk score can be widely implemented, even in settings where cardiovascular risk factors are
unknown. Finally, our validation study in two diverse external cohorts showed that an in-
creased risk score was associated with a very similar increased incidence of CKD in the deriva-
tion and validation cohorts.
In conclusion, we have developed and externally validated a risk score for CKD in HIV in-
fection that has direct clinical relevance for patients and clinicians to weigh the benefits of cer-
tain antiretrovirals against the risk of CKD, and to identify those at greatest risk of CKD.
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data collection: C. J. H. M. Duijf-van de Ven. HagaZiekenhuis, Den Haag: HIV treating physi-
cians: E. F. Schippers , C. van Nieuwkoop, R. W. Brimicombe. HIV nurse consultant: J. M. van
IJperen. Data collection: G. van der Hut. HIV clinical virologist/chemist: P. F. H. Franck. HIV
Focus Centrum (DC Klinieken), Amsterdam: HIV treating physician: A. van Eeden .H I V
nurse consultants: W. Brokking, M. Groot. HIV clinical virologists/chemists: M. Damen, I. S.
Kwa. Isala Klinieken, Zwolle: HIV treating physicians: P. H. P. Groeneveld , J. W. Bouwhuis.
HIV nurse consultants: J. F. van den Berg, A. G. W. van Hulzen. Data collection: G. L. van der
Bliek, P. C. J. Bor. HIV clinical virologists/chemists: P. Bloembergen, M. J. H. M. Wolfhagen,
G. J. H. M. Ruijs. Kennemer Gasthuis, Haarlem: HIV treating physicians: S. F. L. van
Lelyveld , R. Soetekouw. HIV nurse consultants: N. Hulshoff, L. M. M. van der Prijt, M. Schoe-
maker. Data collection: N. Bermon. HIV clinical virologists/chemists: W. A. van der Reijden,
R. Jansen, B. L. Herpers, D. Veenendaal. Leids Universitair Medisch Centrum, Leiden: HIV
treating physicians: F. P. Kroon , S. M. Arend, M. G. J. de Boer, M. P. Bauer, H. Jolink, A. M.
Vollaard. HIV nurse consultants: W. Dorama, C. Moons. HIV clinical virologists/chemists: E.
C. J. Claas, A. C. M. Kroes. Maasstad Ziekenhuis, Rotterdam: HIV treating physicians: J. G.
den Hollander , K. Pogany. HIV nurse consultants: M. Kastelijns, J. V. Smit, E. Smit. Data
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PLOS Medicine | DOI:10.1371/journal.pmed.1001809 March 31, 2015 16 / 31collection: M. Bezemer, T. van Niekerk. HIV clinical virologist/chemist: O. Pontesilli. Maas-
tricht UMC+, Maastricht: HIV treating physicians: S. H. Lowe , A. Oude Lashof, D. Post-
houwer. HIV nurse consultants: R. P. Ackens, J. Schippers, R. Vergoossen. Data collection: B.
Weijenberg Maes. HIV clinical virologists/chemists: P. H. M. Savelkoul, I. H. Loo. MC Zuider-
zee, Lelystad: HIV treating physicians: S. Weijer , R. El Moussaoui. HIV nurse consultant: M.
Heitmuller. Data collection: M. Heitmuller. Medisch Centrum Alkmaar, Alkmaar: HIV treat-
ing physicians: W. Kortmann , G. van Twillert , J. W. T. Cohen Stuart, B. M. W. Diederen.
HIV nurse consultants and data collection: D. Pronk, F. A. van Truijen-Oud. HIV clinical vi-
rologists/chemists: W. A. van der Reijden, R. Jansen. Medisch Centrum Haaglanden, Den
Haag: HIV treating physicians: E. M. S. Leyten , L. B. S. Gelinck. HIV nurse consultants: A.
van Hartingsveld, C. Meerkerk, G. S. Wildenbeest. HIV clinical virologists/chemists: J. A. E. M.
Mutsaers, C. L. Jansen. Medisch Centrum Leeuwarden, Leeuwarden: HIV treating physicians:
M. G. A. van Vonderen , D. P. F. van Houte. HIV nurse consultants: K. Dijkstra, S. Faber. HIV
clinical virologist/chemist: J Weel. Medisch Spectrum Twente, Enschede: HIV treating physi-
cians: G. J. Kootstra , C. E. Delsing. HIV nurse consultants: M. van der Burg-van de Plas, H.
Heins. Data collection: E. Lucas. Onze Lieve Vrouwe Gasthuis, Amsterdam: HIV treating
physicians: K. Brinkman , P. H. J. Frissen, W. L. Blok, W. E. M. Schouten. HIV nurse consul-
tants: A. S. Bosma, C. J. Brouwer, G. F. Geerders, K. Hoeksema, M. J. Kleene, I. B. van der
Meché, A. J. M. Toonen, S. Wijnands. HIV clinical virologists/chemists: M. L. van Ogtrop, R.
Jansen. Radboud UMC, Nijmegen: HIV treating physicians: P. P. Koopmans, M. Keuter, A. J.
A. M. van der Ven, H. J. M. ter Hofstede, A. S. M. Dofferhoff, R. van Crevel. HIV nurse consul-
tants: M. Albers, M. E. W. Bosch, K. J. T. Grintjes-Huisman, B. J. Zomer. HIV clinical virolo-
gist/chemist: F. F. Stelma. HIV clinical pharmacology consultant: D. Burger. Rijnstate,
Arnhem: HIV treating physicians: C. Richter , J. P. van der Berg, E. H. Gisolf. HIV nurse con-
sultants: G. ter Beest, P. H. M. van Bentum, N. Langebeek. HIV clinical virologists/chemists: R.
Tiemessen, C. M. A. Swanink. Sint Lucas Andreas Ziekenhuis, Amsterdam: HIV treating
physicians: J. Veenstra , K. D. Lettinga. HIV nurse consultants: M. Spelbrink, H. Sulman. Data
collection: M. Spelbrink, E. Witte. HIV clinical virologists/chemists: M. Damen, P. G. H. Peer-
booms. Slotervaartziekenhuis, Amsterdam: HIV treating physicians: J. W. Mulder, S. M. E.
Vrouenraets, F. N. Lauw. HIV nurse consultants: M. C. van Broekhuizen, H. Paap, D. J. Vlas-
blom. Data collection: E. Oudmaijer Sanders. HIV clinical virologists/chemists: P. H. M. Smits,
A. W. Rosingh. Stichting Medisch Centrum Jan van Goyen, Amsterdam: HIV treating physi-
cians: D. W. M. Verhagen. HIV nurse consultant: J. Geilings. St Elisabeth Ziekenhuis, Til-
burg: HIV treating physicians: M. E. E. van Kasteren , A. E. Brouwer. HIV nurse consultants
and data collection: B. A. F. M. de Kruijf-van de Wiel, M. Kuipers, R. M. W. J. Santegoets, B.
van der Ven. HIV clinical virologists/chemists: J. H. Marcelis, A. G. M. Buiting, P. J. Kabel.
Universitair Medisch Centrum Groningen, Groningen: HIV treating physicians: W. F. W.
Bierman , H. G. Sprenger, E. H. Scholvinck, S. van Assen, K. R. Wilting, Y. Stienstra. HIV
nurse consultants: H. de Groot-de Jonge, P. A. van der Meulen, D. A. de Weerd. HIV clinical
virologists/chemists: H. G. M. Niesters, A. Riezebos-Brilman, C. C. van Leer-Buter. Universi-
tair Medisch Centrum Utrecht, Utrecht: HIV treating physicians: A. I. M. Hoepelman ,M .
M. E. Schneider, T. Mudrikova, P. M. Ellerbroek, J. J. Oosterheert, J. E. Arends, R. E. Barth, M.
W. M. Wassenberg. HIV nurse consultants: D. H. M. van Elst-Laurijssen, L. M. Laan, E. E. B.
van Oers-Hazelzet, J. Patist, S. Vervoort, Data collection: H. E. Nieuwenhuis, R. Frauenfelder.
HIV clinical virologists/chemists: R. Schuurman, F. Verduyn-Lunel, A. M. J. Wensing. VU
Medisch Centrum, Amsterdam: HIV treating physicians: E. J. G. Peters , M. A. van Agtmael,
R. M. Perenboom, M. Bomers, J. de Vocht. HIV nurse consultants: L. J. M. Elsenburg. HIV
clinical virologists/chemists: A. M. Pettersson, C. M. J. E. Vandenbroucke-Grauls, C. W. Ang.
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PLOS Medicine | DOI:10.1371/journal.pmed.1001809 March 31, 2015 17 / 31Wilhelmina Kinderziekenhuis, University Medical Center Utrecht, Utrecht: HIV treating
physicians: S. P. M. Geelen, T. F. W. Wolfs, L. J. Bont. HIV nurse consultant: N. Nauta.
Coordinating centre: Stichting HIV Monitoring Director: P. Reiss. Data analysis: D. O.
Bezemer, L. Gras, A. I. van Sighem, C. Smit. Data management and quality control: S. Zaheri,
M. Hillebregt, V. Kimmel, Y. Tong. Data monitoring: B. Lascaris, R. van den Boogaard, P.
Hoekstra, A. de Lang, M. Berkhout, S. Grivell, A. Jansen. Data collection: L. de Groot, M. van
den Akker, D. Bergsma, C. Lodewijk, R. Meijering, B. Peeck, M. Raethke, C. Ree, R. Regtop, Y.
Ruijs, M. Schoorl, E. Tuijn, L. Veenenberg, T. Woudstra, Y. Bakker, A. de Jong, M. Broekhoven,
E. Claessen, M. J. Rademaker, L. Munjishvili, E. Kruijne. Patient registration: B. Tuk.
(2) Aquitaine Cohort (France)
Principal investigator: F. Dabis.
Scientific committee: F. Bonnet, F. Dabis, M. Dupon, G. Chêne, D. Breilh, H. Fleury, D.
Malvy, P. Mercié, I. Pellegrin, P. Morlat, D. Neau, J. L. Pellegrin, S. Bouchet, V. Gaborieau, D.
Lacoste, S. Tchamgoué, R. Thiébaut.
Composition of the Groupe d’Epidémiologie Clinique du Sida en Aquitaine. Epidemiol-
ogy and biostatistics: G. Chêne, F. Dabis, R. Thiébaut, M. Bruyand, S. Lawson-Ayayi, L.
Wittkop.
Clinical and biological hospital units. Bordeaux University Hospital: P. Morlat (F. Bon-
net, N. Bernard, M. Hessamfar, D. Lacoste, M. A. Vandenhende); M. Dupon (F. A. Dauchy, H.
Dutronc), M. Longy-Boursier (P. Mercié, P. Duffau, J. Roger Schmeltz), D. Malvy (T. Pistone,
M. C. Receveur), D. Neau (C. Cazanave, A. Ochoa, M. O. Vareil), J. L. Pellegrin (J. F. Viallard,
C. Greib, E. Lazaro); H. Fleury (M. E. Lafon, S. Reigadas, P. Trimoulet); D. Breilh; M. Molimard
(S. Bouchet, K. Titier); J. F. Moreau (I. Pellegrin); F. Haramburu, G. Miremont-Salamé. Arca-
chon Hospital: A. Dupont. Dax Hospital: Y. Gerard (L. Caunègre, K. André). Bayonne Hos-
pital: F. Bonnal (S. Farbos, M. C. Gemain). Libourne Hospital: J. Ceccaldi (S. Tchamgoué).
Mont-de-Marsan Hospital: S. De Witte (C. Courtault). Pau Hospital: E. Monlun (V. Gabor-
ieau). Périgueux Hospital: P. Lataste (J. P. Meraud). Villeneuve-sur-Lot Hospital: I. Chossat.
Permanent team: M. J. Blaizeau, M. Bruyand, V. Conte, M. Decoin, J. Delaune, S. Delveaux,
F. Diarra, C. D’Ivernois, A. Frosch, S. Geffard, C. Hannapier, S. Lawson-Ayayi, E. Lenaud, O.
Leleux, F. Le Marec, J. Leray, I. Louis, G. Palmer, A. Pougetoux, X. Sicard, D. Touchard B. Uwa-
maliya-Nziyumvira.
(3) Australian HIV Observational Database (Australia)
Central coordination: M. Law, K. Petoumenos, H. McManus, S. Wright, C. Bendall (Sydney,
New South Wales).
Participating physicians: R. Moore, S. Edwards, J. Hoy, K. Watson, N. Roth, J. Nicholson
(Melbourne, Victoria); M. Bloch, T. Franic, D. Baker, R. Vale, A. Carr, D. Cooper (Sydney,
New South Wales); J. Chuah, M. Ngieng (Gold Coast, Queensland); D. Nolan, J. Skett (Perth,
Western Australia).
(4) BASS (Spain)
Central coordination: G. Calvo, F. Torres, S. Mateu (Barcelona).
Participating physicians: P. Domingo, M. A. Sambeat, J. Gatell, E. Del Cacho, J. Cadafalch,
M. Fuster (Barcelona); C. Codina, G. Sirera, A. Vaqué (Badalona).
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Coordination: S. De Wit, N. Clumeck, M. Delforge, C. Necsoi.
Participating physicians: N. Clumeck, S. De Wit, A. F. Gennotte, M. Gerard, K. Kabeya, D.
Konopnicki, A. Libois, C. Martin, M. C. Payen, P. Semaille, Y. Van Laethem.
(6) Community Programs for Clinical Research on AIDS (US)
Central coordination: J. Neaton, G. Bartsch, W. M. El-Sadr, E. Krum, G. Thompson, D.
Wentworth.
Participating physicians: R. Luskin-Hawk (Chicago, Illinois); E. Telzak (Bronx, New
York); W. M. El-Sadr (Harlem, New York); D. I. Abrams (San Francisco, California); D. Cohn
(Denver, Colorado); N. Markowitz (Detroit, Michigan); R. Arduino (Houston, Texas); D.
Mushatt (New Orleans, Louisiana); G. Friedland (New Haven, Connecticut); G. Perez (New-
ark, New Jersey); E. Tedaldi (Philadelphia, Pennsylvania); E. Fisher (Richmond, Virginia); F.
Gordin (Washington, District of Columbia); L. R. Crane (Detroit, Michigan); J. Sampson
(Portland, Oregon); J. Baxter (Camden, New Jersey).
(7) EuroSIDA (multinational)
Coordinating centre: J. Lundgren, O. Kirk, A. Mocroft, A. Cozzi-Lepri, D. Grint, D. Podlekar-
eva, J. Kjær, L. Peters, J. Reekie, J. Kowalska, J. Tverland, A. H. Fischer, J. Nielsen.
Participating countries and physicians (
#national coordinator):
Argentina: M. Losso
#, C. Elias, Hospital J. M. Ramos Mejia, Buenos Aires.
Austria: N. Vetter
#, Pulmologisches Zentrum der Stadt Wien, Vienna; R. Zangerle, Medical
University Innsbruck, Innsbruck.
Belarus: I. Karpov
#, A. Vassilenko, Belarus State Medical University, Minsk; V. M. Mitsura,
Gomel State Medical University, Gomel; O. Suetnov, Regional AIDS Centre, Svetlogorsk.
Belgium: N. Clumeck
#, S. De Wit, M. Delforge, Saint-Pierre Hospital, Brussels; R. Colebun-
ders, Institute of Tropical Medicine, Antwerp; L. Vandekerckhove, University Ziekenhuis
Gent, Gent.
Bosnia-Herzegovina: V. Hadziosmanovic
#, Klinicki Centar Univerziteta Sarajevo, Sarajevo.
Bulgaria: K. Kostov
#, Infectious Diseases Hospital, Sofia.
Croatia: J. Begovac
#, University Hospital of Infectious Diseases, Zagreb.
Czech Republic: L. Machala
#, D. Jilich, Faculty Hospital Bulovka, Prague; D. Sedlacek,
Charles University Hospital, Plzen.
Denmark: J. Nielsen
#, G. Kronborg, T. Benfield, M. Larsen, Hvidovre Hospital, Copenha-
gen; J. Gerstoft, T. Katzenstein, A.-B. E. Hansen, P. Skinhøj, Rigshospitalet, Copenhagen; C. Pe-
dersen, Odense University Hospital, Odense; L. Ostergaard, Skejby Hospital, Aarhus.
Estonia: K. Zilmer
#, West-Tallinn Central Hospital, Tallinn; J. Smidt, Nakkusosakond
Siseklinik, Kohtla-Järve.
Finland: M. Ristola
#, Helsinki University Central Hospital, Helsinki.
France: C. Katlama
#, Hôpital de la Pitié-Salpétière, Paris; J.-P. Viard, Hôpital Necker-En-
fants Malades, Paris; P.-M. Girard, Hospital Saint-Antoine, Paris; J. M. Livrozet, Hôpital
Edouard Herriot, Lyon; P. Vanhems, University Claude Bernard, Lyon; C. Pradier, Hôpital de
l’Archet, Nice; F. Dabis, D. Neau, Unité INSERM, Bordeaux.
Germany: J. Rockstroh
#, Universitäts Klinik Bonn; R. Schmidt, Medizinische Hochschule
Hannover, Hannover; J. van Lunzen, O. Degen, University Medical Center Hamburg-Eppen-
dorf, Infectious Diseases Unit, Hamburg; H. J. Stellbrink, IPM Study Center, Hamburg; S.
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PLOS Medicine | DOI:10.1371/journal.pmed.1001809 March 31, 2015 19 / 31Staszewski, University Hospital Frankfurt, Frankfurt; M. Bickel, Medizinische Poliklinik, Mu-
nich; G. Fätkenheuer, Universität Köln, Cologne.
Greece: J. Kosmidis
#, P. Gargalianos, G. Xylomenos, J. Perdios, Athens General Hospital,
Athens; G. Panos, A. Filandras, E. Karabatsaki, 1st IKA Hospital, Athens; H. Sambatakou,
Ippokration Genereal Hospital, Athens.
Hungary: D. Banhegyi
#, Szent Lásló Hospital, Budapest.
Ireland: F. Mulcahy
#, St. James’s Hospital, Dublin.
Israel: I. Yust
#, D. Turner, M. Burke, Ichilov Hospital, Tel Aviv; S. Pollack, G. Hassoun,
Rambam Medical Center, Haifa; S. Maayan, Hadassah University Hospital, Jerusalem.
Italy: S. Vella
#, Istituto Superiore di Sanità, Rome; R. Esposito, I. Mazeu, C. Mussini, Uni-
versità Modena, Modena; C. Arici, Ospedale Riuniti, Bergamo; R. Pristera, Ospedale Generale
Regionale, Bolzano; F. Mazzotta, A. Gabbuti, Ospedale Sante Maria Annunziata, Firenze; V.
Vullo, M. Lichtner, University di Roma la Sapienza, Rome; A. Chirianni, E. Montesarchio, M.
Gargiulo, Presidio Ospedaliero AD Cotugno, Monaldi Hospital, Napoli; G. Antonucci, A.
Testa, P. Narciso, C. Vlassi, M. Zaccarelli, Istituto Nazionale Malattie Infettive Lazzaro Spallan-
zani, Rome; A. Lazzarin, A. Castagna, N. Gianotti, Ospedale San Raffaele, Milan; M. Galli, A.
Ridolfo, Ospedale Luigi Sacco, Milan; A. d’Arminio Monforte, Istituto di Malattie Infettive e
Tropicali, Milan.
Latvia: B. Rozentale
#, I. Zeltina, Infectology Centre of Latvia, Riga.
Lithuania: S. Chaplinskas
#, Lithuanian AIDS Centre, Vilnius.
Luxembourg: R. Hemmer
#, T. Staub, Centre Hospitalier, Luxembourg.
Netherlands: P. Reiss
#, Academisch Medisch Centrum bij de Universiteit van Amsterdam,
Amsterdam.
Norway: V. Ormaasen
#, A. Maeland, J. Bruun, Ullevål Hospital, Oslo.
Poland: B. Knysz
# J. Gasiorowski, Medical University, Wroclaw; A. Horban, E. Bakowska,
Centrum Diagnostyki i Terapii AIDS, Warsaw; A. Grzeszczuk, R. Flisiak, Medical University,
Bialystok; A. Boron-Kaczmarska, M. Pynka, M. Parczewski, Medical Univesity, Szczecin; M.
Beniowski, E. Mularska, Osrodek Diagnostyki i Terapii AIDS, Chorzow; H. Trocha, Medical
University, Gdansk; E. Jablonowska, E. Malolepsza, K. Wojcik, Wojewodzki Szpital Specjalis-
tyczny, Lodz.
Portugal: F. Antunes
#, M. Doroana, L. Caldeira, Hospital Santa Maria, Lisbon; K. Man-
sinho, Hospital de Egas Moniz, Lisbon; F. Maltez, Hospital Curry Cabral, Lisbon.
Romania: D. Duiculescu
#, Spitalul Clinic Dr. Victor Babeş, Bucarest.
Russia: A. Rakhmanova
#, Medical Academy Botkin Hospital, Saint Petersburg; N. Zakhar-
ova, St. Petersburg AIDS Centre, Saint Petersburg; S. Buzunova, Novgorod Centre for AIDS,
Novgorod.
Serbia: D. Jevtovic
#, Institute for Infectious and Tropical Diseases, Belgrade.
Slovakia: M. Mokráš
#, D. Staneková, Dérer Hospital, Bratislava.
Slovenia: J. Tomazic
#, University Clinical Centre Ljubljana, Ljubljana.
Spain: J. González-Lahoz
#, V. Soriano, P. Labarga, J. Medrano, Hospital Carlos III, Madrid;
S. Moreno, J. M. Rodriguez, Hospital Ramon y Cajal, Madrid; B. Clotet, A. Jou, R. Paredes, C.
Tural, J. Puig, I. Bravo, Hospital Germans Trias i Pujol, Badalona; J. M. Gatell, J. M. Miró, Hos-
pital Clinic i Provincial, Barcelona; P. Domingo, M. Gutierrez, G. Mateo, M. A. Sambeat, Hos-
pital Sant Pau, Barcelona.
Sweden: A. Karlsson
#, Venhaelsan-Sodersjukhuset, Stockholm; L. Flamholc, Malmö Uni-
versity Hospital, Malmö.
Switzerland: B. Ledergerber
#, R. Weber, University Hospital, Zürich; P. Francioli, M. Cavas-
sini, Centre Hospitalier Universitaire Vaudois, Lausanne; B. Hirschel, E. Boffi, Hospital
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Elzi, University Hospital Basel, Basel.
Ukraine: E. Kravchenko
#, N. Chentsova, Kiev Centre for AIDS, Kiev; V. Frolov, G. Kutsyna,
Luhansk State Medical University; Luhansk; S. Servitskiy, Odessa Region AIDS Center, Odessa;
M. Krasnov, Kharkov State Medical University, Kharkov.
United Kingdom: S. Barton
#, St. Stephen’s Clinic, Chelsea and Westminster Hospital, Lon-
don; A. M. Johnson, D. Mercey, A. Phillips, M. A. Johnson, A. Mocroft, Royal Free and Univer-
sity College Medical School, London; M. Murphy, Medical College of Saint Bartholomew’s
Hospital, London; J. Weber, G. Scullard, Imperial College School of Medicine at St. Mary’s,
London; M. Fisher, Royal Sussex County Hospital, Brighton; C. Leen, Western General Hospi-
tal, Edinburgh.
(8) HivBivus (Sweden)
Central coordination: L. Morfeldt, G. Thulin, A. Sundström.
Participating physicians: B. Åkerlund (Huddinge); K. Koppel, A. Karlsson (Stockholm); L.
Flamholc, C. Håkangård (Malmö).
(9) ICONA Cohort (Italy)
Board of Directors: M. Moroni (Chair), G. Angarano, A. Antinori, O. Armignacco, A. d’Armi-
nio Monforte, F. Castelli, R. Cauda, G. Di Perri, M. Galli, R. Iardino, G. Ippolito, A. Lazzarin,
C. F. Perno, F. von Schloesser, P. Viale
Scientific secretary: Ad ’Arminio Monforte, A. Antinori, A. Castagna, F. Ceccherini-Silber-
stein, A. Cozzi-Lepri, E. Girardi, S. Lo Caputo, C. Mussini, M. Puoti
ICONA steering committee: M. Andreoni, A. Ammassari, A. Antinori, A. d’Arminio Mon-
forte, C. Balotta, P. Bonfanti, S. Bonora, M. Borderi, R. Capobianchi, A. Castagna, F. Ceccher-
ini-Silberstein, A. Cingolani, P. Cinque, A. Cozzi-Lepri, A. De Luca, A. Di Biagio, E. Girardi, N.
Gianotti, A. Gori, G. Guaraldi, G. Lapadula, M. Lichtner, S. Lo Caputo, G. Madeddu, F. Mag-
giolo, G. Marchetti, S. Marcotullio, L. Monno, C. Mussini, M. Puoti, E. Quiros Roldan, S.
Rusconi
Statistical and monitoring team: A. Cozzi-Lepri, P. Cicconi, I. Fanti, T. Formenti, L. Galli,
P. Lorenzini.
Participating physicians and centres: A. Giacometti, A. Costantini (Ancona); G. Angar-
ano, L. Monno, C. Santoro (Bari); F. Maggiolo, C. Suardi (Bergamo); P. Viale, E. Vanino, G.
Verucchi (Bologna); F. Castelli, E. Quiros Roldan, C. Minardi (Brescia); T. Quirino, C. Abeli
(Busto Arsizio); P. E. Manconi, P. Piano (Cagliari); J. Vecchiet, K. Falasca (Chieti); L. Sighinolfi,
D. Segala (Ferrara); F. Mazzotta, S. Lo Caputo (Firenze); G. Cassola, G. Viscoli, A. Alessandrini,
R. Piscopo, G. Mazzarello (Genova); C. Mastroianni, V. Belvisi (Latina); P. Bonfanti, I. Car-
amma (Lecco); A. P. Castelli (Macerata); M. Galli, A. Lazzarin, G. Rizzardini, M. Puoti, A.
d’Arminio Monforte, A. L. Ridolfo, R. Piolini, A. Castagna, S. Salpietro, L. Carenzi, M. C.
Moioli, P. Cicconi, G. Marchetti (Milano); C. Mussini, C. Puzzolante (Modena); A. Gori, G.
Lapadula (Monza); N. Abrescia, A. Chirianni, M. G. Guida, M. Onofrio (Napoli); F. Baldelli, D.
Francisci (Perugia); G. Parruti, T. Ursini (Pescara); G. Magnani, M. A. Ursitti (Reggio Emilia);
R. Cauda, M. Andreoni, A. Antinori, V. Vullo, A. Cingolani, A. d’Avino, A. Ammassari, L.
Gallo, E. Nicastri, R. Acinapura, M. Capozzi, R. Libertone, G. Tebano (Roma); A. Cattelan
(Rovigo); M. S. Mura, G. Madeddu (Sassari); P. Caramello, G. Di Perri, G. C. Orofino, S.
Bonora, M. Sciandra (Torino); G. Pellizzer, V. Manfrin (Vicenza).
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Central coordination: C. Pradier, E. Fontas, K. Dollet, C. Caissotti.
Participating physicians: P. Dellamonica, P. M. Roger, E. Bernard, E. Cua, F. De Salvador-
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Background
About 35 million people are currently infected with HIV, the virus that causes AIDS. HIV
destroys CD4 lymphocytes and other immune system cells, leaving infected individuals sus-
ceptible to other infections. HIV infection can be controlled, but not cured, using combina-
tion antiretroviral therapy (cART), and, nowadays, the life expectancy of many HIV-
positive individuals is similar to that of HIV-negative people. HIV-positive individuals nev-
ertheless experience some illnessesmorefrequently than HIV-negativepeopledo. For exam-
ple, up to a third of HIV-positive individuals develop chronic kidney disease (CKD), which
is associated with an increased risk of cardiovascular disease and death. Persons with CKD
may have an impaired effect of the filtration units in the kidneys that remove waste products
and excess water from the blood to make urine, thereby leading to a reduced blood filtration
rate (the estimated glomerular filtration rate [eGFR]) and waste product accumulation in
the blood. Symptoms of CKD, which rarely occur until the disease is advanced, include
tiredness, swollen feet, and frequent urination. Advanced stages of CKD cannot be cured,
but its progression can be slowed by, for example,controlling hypertension (high blood
pressure) and diabetes (two CDK risk factors) and by adopting a healthy lifestyle.
Why Was This Study Done?
The burden of CKD may increase among HIV-positive individuals as they age, and clini-
cians need to know which individuals are at high risk of developing CKD when choosing
cART regimens for their patients. In addition, clinicians need to be able to identify those
HIV-positive individuals at greatest risk of CKD so that they can monitor them for early
signs of kidney disease. Some antiretroviral drugs—for example, tenofovir and atazanavir/
ritonavir (a boosted protease inhibitor)—are associated with kidney damage. Clinicians
may need to weigh the benefits and risks of giving such potentially nephrotoxic drugs to
individuals who already have a high CKD risk. Here, the researchers develop and validate
a simple, widely applicable risk score (a risk prediction model) for CKD among HIV-posi-
tive individuals and investigate the relationship between CKD and potentially nephrotoxic
antiretroviral drugs among individuals with different CKD risk score profiles.
What Did the Researchers Do and Find?
To develop their CKD risk score, the researchers used clinical and demographic data col-
lected from 17,954 HIV-positive individuals enrolled in the Data Collection on Adverse
Events of Anti-HIV Drugs (D:A:D) study who had an eGFR > 60 ml/min/1.73 m
2 and
were not taking a potentially nephrotoxic antiretroviral at baseline. During 103,185 per-
son-years of follow-up, 641 individuals developed CKD. Older age, intravenous drug use,
hepatitis C coinfection, lower baseline eGFR, female gender, lower CD4 count nadir, hy-
pertension, diabetes, and cardiovascular disease predicted CKD. The researchers included
these nine factors in their risk score model (which is available online) and defined three
risk groups: low (risk score < 0), medium (risk score 0–4), and high (risk score   5) risk
of CKD development in the next five years. Specifically, there was a 1 in 393, 1 in 47, and 1
in 6 chance of developing CKD in the next five years in the low, medium, and high risk
groups, respectively. Because some patients started to use potentially nephrotoxic antire-
troviral drugs during follow-up, the researchers were able to use their risk score model to
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tional patient to develop CKD over five years in each risk group. This “number needed to
harm” (NNTH) for patients starting treatment with tenofovir, atazanavir/ritonavir, or an-
other boosted protease inhibitor was 739, 88, and 9 in the low, medium, and high risk
groups, respectively. Finally, the researchers validated the accuracy of their risk score in
two independent HIV study groups.
What Do These Findings Mean?
These findings provide a simple, validated risk score for CKD and indicate that the NNTH
when starting potentially nephrotoxic antiretrovirals was low among HIV-positive indi-
viduals at the highest risk of CKD (i.e., treating just nine individuals with nephrotoxic an-
tiretroviral drugs will likely lead to an additional case of CKD in five years). Although
various aspects of the study, including the lack of data on race, limit the accuracy of these
findings, these findings highlight the need for monitoring, screening, and chronic disease
prevention to minimize the risk of HIV-positive individuals developing diabetes, hyper-
tension, or cardiovascular disease, or becoming coinfected with hepatitis C, all of which
contribute to the CKD risk score. Moreover, the development of a tool for estimating an
individual’s five-year risk of developing CKD with or without the addition of potentially
nephrotoxic antiretroviral drugs will enable clinicians and patients to weigh the benefits of
certain antiretroviral drugs against the risk of CKD and make informed decisions about
treatment options.
Additional Information
Please access these websites via the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001809.
￿ Information is available from the US National Institute of Allergy and Infectious Dis-
eases on HIV infection and AIDS
￿ NAM/aidsmap provides basic information about HIV/AIDS, summaries of recent re-
search findings on HIV care and treatment, and personal stories about living with
AIDS/HIV
￿ Information is available from Avert, an international AIDS charity, on many aspects of
HIV/AIDS, including personal stories about living with HIV/AIDS
￿ The World Health Organization provides information on all aspects of HIV/AIDS (in
several languages), including its guidelines on the use of ART for treating and
preventing HIV infection
￿ The UNAIDS World AIDS Day Report 2014 provides up-to-date information about the
AIDS epidemic and efforts to halt it
￿ The UK National Health Service Choices website provides information for patients on
chronic kidney disease, including some personal stories
￿ The US National Kidney Foundation, a not-for-profit organization, provides informa-
tion about chronic kidney disease (in English and Spanish)
￿ A tool for calculating the CDK risk score developed in this study is available
￿ Additional information about the D:A:D study is available
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